Soleno Therapeutics, Inc. (SLNO) Financials

SLNO Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 608.4 million 112.6 million
Dec. 31, 2025 563.8 million 113.7 million
Sept. 30, 2025 599.9 million 105.1 million
June 30, 2025 332.3 million 92.2 million

SLNO Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 25.9 million 16.1 million
Dec. 31, 2025 48.6 million 11.5 million
Sept. 30, 2025 43.6 million 10.0 million
June 30, 2025 -12.6 million 9.7 million

SLNO Net Income

No data available :(

SLNO Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 255.6 million 3.2 million -
Dec. 31, 2025 305.5 million 2.0 million 2.7 million
Sept. 30, 2025 498.9 million 2.1 million 2.8 million
June 30, 2025 286.8 million 49.8 million 2.9 million

SLNO Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 53.1 million
Dec. 31, 2025 54.3 million
Sept. 30, 2025 54.9 million
June 30, 2025 50.5 million

SLNO Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 40000 11.3 million 50.4 million -
Dec. 31, 2025 58000 9.6 million 40.9 million -
Sept. 30, 2025 1000 8.4 million 33.8 million -
June 30, 2025 9000 9.1 million 28.2 million -

SLNO Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 94.6 million 1.2 million
Dec. 31, 2025 91.7 million 863000
Sept. 30, 2025 66.0 million 1.1 million
June 30, 2025 32.7 million 696000

SLNO

Price: $53.01

52 week price:
29.43
90.32

Earnings Per Share: 1.93 USD

P/E Ratio: 27.47

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 110100

Ebitda: -13.8 million

Market Capitalization: 2.8 billion

Links: